1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts

Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts

  • February 2017
  • -
  • Currentpartnering
  • -
  • 717 pages

Summary

Table of Contents

Search Inside

Summary
The Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

Description
The Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in regenerative medicine
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for regenerative medicine and stem cells

The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.

The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 950 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Regenerative Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Regenerative Medicine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Regenerative Medicine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Regenerative Medicine dealmaking with a brief summary followed by a comprehensive listing of Regenerative Medicine deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Regenerative Medicine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Regenerative Medicine partnering deals signed and announced since Jan 2010. The chapter is organized by specific Regenerative Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Regenerative Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Regenerative Medicine partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Regenerative Medicine technologies and products.

Key benefits

Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:
- In-depth understanding of Regenerative Medicine deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Regenerative Medicine agreements with numerous real life case studies
- Detailed access to actual Regenerative Medicine contracts entered into by leading biopharma companies
- Identify most active Regenerative Medicine dealmakers since 2010
- Insight into terms included in a Regenerative Medicine partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Regenerative Medicine trends and structure of deals entered into by leading companies worldwide.

Regenerative Medicine Partnering Terms and Agreements includes:
- Trends in Regenerative Medicine dealmaking in the biopharma industry since 2010
- Analysis of Regenerative Medicine deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Regenerative Medicine deals
- Access to Regenerative Medicine contract documents
- Leading Regenerative Medicine deals by value since 2010
- Most active Regenerative Medicine dealmakers since 2010

In Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 950 Regenerative Medicine deals.

Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Autologous Cell Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Autologous Cell Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Autologous Cell Therapy Market: Overview This report provides in-depth region wise and country wise analysis of the autologous cell therapy market. Stakeholders of this report include manufacturers ...

Top 10 Bioprocess Technology Market by Cell Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, Biologics Safety Testing, Tangential Flow Filtration, Virus Filtration & Region - Forecast to 2021

Top 10 Bioprocess Technology Market by Cell Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, Biologics Safety Testing, Tangential Flow Filtration, Virus Filtration & Region - Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global top 10 bioprocess technology market is expected to reach USD 71.03 billion by 2021 from USD 39.30 billion in 2016, at a CAGR of 12.4% from 2016 to 2021. On the basis of type, the market is segmented ...

Stem Cell Therapy Market by Type, Therapeutic Application, Cell Source - Global Forecasts to 2021

Stem Cell Therapy Market by Type, Therapeutic Application, Cell Source - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • February 2017
  • by MarketsandMarkets

The global stem cell therapy market is estimated to grow at a CAGR of 11.0% during 2016 to 2021 to reach USD 145.8 million by 2021. Growth in the global stem cell therapy market is driven by factors such ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.